FDA Approves Biogen Biosimilar for Genentech's Actemra®

By Kevin E. Noonan --

On September 29, the U.S. Food and Drug Administration announced approval of Biogen's Tofidence® (tocilizumab-bavi) as a biosimilar to Genentech's Actemra®, a drug approved for treating COVID-19, rheumatoid arthritis, giant cell arteritis, scleroderma, polyarticular or systemic juvenile idiopathic arthritis, and severe cytokine release syndrome.  Tofidence® is the first Actemra biosimilar, and was approved as an intravenous formulation for treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis.

This approval brings to 44 the number of approved biosimilar products.

Comments

[Onurb]

Hi
Just to let you know that the RSS feed is broken. I wasn't able to get it from multiple readers (either the Atom, RSS 1.0 or RSS 2.0).
This is a pity as I use it to come on the site to read the always interesting posts.
Regards

[Donald Zuhn]

Onurb:

Thank you for the note. Please try subscribing to the following feed: https://feeds.feedblitz.com/patentdocs.

Patent Docs previously offered a feed through Feedburner, but in July of 2021, Feedburner discontinued its email service and we transitioned to Feedblitz for distribution of our daily email newsletters. We noticed in September that Feedblitz was unable to distribute daily emails due to an issue with the Feedburner feed. Therefore, we switched to the Feedblitz feed and that resolved the problem. Upon checking the Feedblitz feed today, it appears to be working for us.

Please note that the RSS link on the weblog was updated in July of 2021 to direct readers to the Feedblitz feed. However, if you are a long time subscriber, it is understandable why you would not have been aware of this update. Sorry for the inconvenience.

Please let us know if you continue to have any issues. Thank you for alerting us to the issue and for reading Patent Docs.

Don